德展健康：参股公司东方略在研重点产品VGX-3100的首个适应症Ⅲ期临床试验已完成全部患者入组

Core Viewpoint - The company Dezheng Health (000813) announced that its associate company Dongfang Lue has completed patient enrollment for the Phase III clinical trial of its key product VGX-3100, which is aimed at treating high-grade cervical precancerous lesions associated with HPV-16 and/or HPV-18 [1] Group 1 - The Phase III clinical trial for VGX-3100 has completed all patient enrollments [1] - Two additional indications for treating high-grade anal and vaginal precancerous lesions associated with HPV-16 and/or HPV-18 have received approval from the National Medical Products Administration, allowing them to proceed directly to Phase II clinical trials [1]